[Effect of prodigiozan and its combination with antibiotics on the course and outcome of the acute experimental purulent inflammation].
D000636:Aminosalicylic Acids / Q000627:therapeutic use; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D004096:Dihydrostreptomycin Sulfate / Q000627:therapeutic use; D007249:Inflammation / Q000188:drug therapy; D051379:Mice; D009336:Necrosis / Q000517:prevention & control; D010404:Penicillin V / Q000627:therapeutic use; D011135:Polysaccharides, Bacterial / Q000627:therapeutic use*; D012706:Serratia marcescens; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013492:Suppuration / Q000188:drug therapy
D000636:Aminosalicylic Acids; D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D011135:Polysaccharides, Bacterial; D004096:Dihydrostreptomycin Sulfate; D010404:Penicillin V
Vliianie prodigiozana i ego sochetaniia s antibiotikami na techenie i iskhod ostrogo éksperimental'nogo gnoĭnogo vospaleniia.